



Contacts:  
At Financial Relations Board:  
Tim Grace  
312.640-6667 or [tgrace@mww.com](mailto:tgrace@mww.com)

At GeoVax:  
Bob McNally  
404.727.0971 or [bmcnally@geovax.com](mailto:bmcnally@geovax.com)

## **GEOVAX TO WEBCAST ITS PRESENTATION AT THE BIO CEO & INVESTOR 2009 CONFERENCE**

*Webcast to be Held by Thomson Reuters*

**ATLANTA - February 4, 2009** - GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that its Corporate Presentation at the BIO CEO & Investor Conference 2009 will be webcast live by Thomson Reuters. The Conference will be held at the Waldorf-Astoria Hotel in New York City on February 9 and 10, 2009.

Dr. McNally, CEO and President of GeoVax Labs, Inc., will present an overview of GeoVax's vaccine technology and will report the latest progress on the Company's Phase 2a preventative human vaccine trial and plans for upcoming therapeutic human vaccine trials.

GeoVax's live webcast coverage is scheduled to commence at 11:00 AM Eastern, on February 10, 2009. The presentation may be accessed by visiting the Company's website at:

<http://www.geovax.com> or  
[http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GOVX&item\\_id=2086228](http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GOVX&item_id=2086228)

Participants can log-in approximately 15 minutes prior to the scheduled presentation in order to register and download any necessary software. A replay of the webcast will also be available on the Company's website following the event for a period of 90 days.

The BIO CEO & Investor Conference is the preeminent gathering of cutting edge biotechnology companies, represented by senior executives, presenting their achievements to institutional investors, industry analysts and portfolio senior executives. Presenting companies were selected through a competitive screening process with a focus on their potential to deliver near-term clinical accomplishments in areas of unmet medical need. The expected attendance at the conference will include representatives from nearly 80 investment firms with a specific interest in life science companies. Among others, participating investment firms will include Goldman Sachs & Co., Hambrecht & Quist Capital, Legg Mason and Morgan Stanley.

"We feel privileged to be among a select group of biotech companies showcasing our technologies to an elite group of interested investment professionals as well as senior executives from our industry sector," stated Dr. McNally.

**MORE**

## **GeoVax Labs, Inc.**

### **Add 1**

#### **About GeoVax Labs, Inc.**

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1. GeoVax AIDS vaccines also may be effective as a therapeutic treatment for people already infected with the HIV-1 virus.

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a \$15 million IPCAVD grant awarded in late 2007.

#### ***Safe Harbor Statement***

*All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.*

###